BridgeBio Pharma, Inc. (BBIO)
76.53
-0.04
(-0.05%)
USD |
NASDAQ |
Sep 02, 16:00
76.73
+0.20
(+0.26%)
After-Hours: 20:00
BridgeBio Pharma Research and Development Expense (TTM) : 505.38M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 505.38M |
| March 31, 2026 | 467.16M |
| December 31, 2025 | 451.95M |
| September 30, 2025 | 465.89M |
| June 30, 2025 | 473.46M |
| March 31, 2025 | 476.92M |
| December 31, 2024 | 506.46M |
| September 30, 2024 | 506.34M |
| June 30, 2024 | 511.03M |
| March 31, 2024 | 503.82M |
| December 31, 2023 | 455.71M |
| September 30, 2023 | 416.39M |
| June 30, 2023 | 383.76M |
| March 31, 2023 | 384.67M |
| December 31, 2022 | 399.46M |
| September 30, 2022 | 432.31M |
| Date | Value |
|---|---|
| June 30, 2022 | 444.10M |
| March 31, 2022 | 437.66M |
| December 31, 2021 | 452.58M |
| September 30, 2021 | 419.00M |
| June 30, 2021 | 406.74M |
| March 31, 2021 | 391.38M |
| December 31, 2020 | 337.05M |
| September 30, 2020 | 304.36M |
| June 30, 2020 | 267.59M |
| March 31, 2020 | 233.32M |
| December 31, 2019 | 209.95M |
| September 30, 2019 | 203.66M |
| June 30, 2019 | 179.53M |
| March 31, 2019 | 151.10M |
| December 31, 2018 | 140.07M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Ionis Pharmaceuticals, Inc. | 923.08M |
| Pfizer Inc. | 10.82B |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| BioMarin Pharmaceutical, Inc. | 766.68M |